ICL

Prezzo ICL Group Ltd (ADRs)

Closed
ICL
$6,37
+$0,37(+6,16%)

*Data last updated: 2026-05-10 15:38 (UTC+8)

As of 2026-05-10 15:38, ICL Group Ltd (ADRs) (ICL) is priced at $6,37, with a total market cap of $8,22B, a P/E ratio of 32,60, and a dividend yield of 0,03%. Today, the stock price fluctuated between $6,24 and $6,41. The current price is 2,08% above the day's low and 0,62% below the day's high, with a trading volume of 2,97M. Over the past 52 weeks, ICL has traded between $5,08 to $6,41, and the current price is -0,62% away from the 52-week high.

ICL Key Stats

Yesterday's Close$6,00
Market Cap$8,22B
Volume2,97M
P/E Ratio32,60
Dividend Yield (TTM)0,03%
Dividend Amount$0,04
Diluted EPS (TTM)0,17
Net Income (FY)$226,00M
Revenue (FY)$7,15B
Earnings Date2026-05-13
EPS Estimate0,10
Revenue Estimate$1,92B
Shares Outstanding1,37B
Beta (1Y)0.879
Ex-Dividend Date2026-03-10
Dividend Payment Date2026-03-25

About ICL

ICL Group Ltd, together with its subsidiaries, operates as a specialty minerals and chemicals company worldwide. It operates in four segments: Industrial Products, Potash, Phosphate Solutions, and Innovative Ag Solutions (IAS). The Industrial Products segment produces bromine out of a solution that is a by-product of the potash production process, as well as bromine-based compounds; produces various grades of potash, salt, magnesium chloride, and magnesia products; and produces and markets phosphorous-based flame retardants and other phosphorus-based products. The Potash segment extracts potash from the Dead Sea; mines and produces potash and salt; produces Polysulphate; produces, markets, and sells magnesium and magnesium alloys, as well as related by-products, including chlorine and sylvinite; and sells salt. The Phosphate Solutions segment uses phosphate commodity products to produce specialty products; produces and markets phosphate-based fertilizers, as well as sulphuric acid, green phosphoric acid, and phosphate fertilizers; and manufactures thermal phosphoric acid for various industrial end markets, such as oral care, cleaning products, paints and coatings, water treatment, asphalt modification, construction, and metal treatment. It also develops and produces functional food ingredients and phosphate additives for use in the processed meat, poultry, seafood, dairy, beverage, and baked goods markets; and produces milk and whey proteins for the food ingredients industry. The IAS segment develops, manufactures, markets, and sells fertilizers based primarily on nitrogen, potash, and phosphate, including water soluble specialty, liquid, soluble, and controlled-release fertilizers. It sells its products through marketing companies, agents, and distributors. The company was formerly known as Israel Chemicals Ltd. and changed its name to ICL Group Ltd in May 2020. The company was founded in 1968 and is headquartered in Tel Aviv, Israel.
SectorBasic Materials
IndustryAgricultural Inputs
CEOElad Aharonson
HeadquartersTel Aviv,None,IL

ICL Group Ltd (ADRs) (ICL) FAQ

What's the stock price of ICL Group Ltd (ADRs) (ICL) today?

x
ICL Group Ltd (ADRs) (ICL) is currently trading at $6,37, with a 24h change of +6,16%. The 52-week trading range is $5,08–$6,41.

What are the 52-week high and low prices for ICL Group Ltd (ADRs) (ICL)?

x

What is the price-to-earnings (P/E) ratio of ICL Group Ltd (ADRs) (ICL)? What does it indicate?

x

What is the market cap of ICL Group Ltd (ADRs) (ICL)?

x

What is the most recent quarterly earnings per share (EPS) for ICL Group Ltd (ADRs) (ICL)?

x

Should you buy or sell ICL Group Ltd (ADRs) (ICL) now?

x

What factors can affect the stock price of ICL Group Ltd (ADRs) (ICL)?

x

How to buy ICL Group Ltd (ADRs) (ICL) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

ICL Group Ltd (ADRs) (ICL) Latest News

2025-06-17 05:43ICL确认与朝鲜关联个人曾贡献于Cosmos代码库 其代码已移除且无遗留风险Gate News bot 消息,Interchain Labs(ICL)已确认,一名后来被确认与朝鲜有关联的个人在 2022 年至 2024 年期间受雇于前维护人员期间,曾为 Cosmos 代码库做出贡献。 这位 Cosmos 核心开发人员与安全联盟 (Security Alliance) 和 Asymmetric Research 合作发布了一份安全报告,证实该个人对两个代码库的访问权限有限:cosmos/IAVL 和 cosmos/cosmos-sdk。审查发现,在 SDK v2 取消后,他贡献的大部分代码已被弃用或从路线图中移除,独立审计未发现任何剩余风险或漏洞。 然而,为了提高透明度,ICL 将在下个月在 Cosmos HackerOne 页面上提供双倍赏金,奖励发现与该参与者的 GitHub 帐户“cool-develope”相关的任何符合条件的漏洞的人员。 具体而言,该个人从 2022 年年中到 2024 年 11 月,在 ICL 成立和 Cosmos 第三方维护模式结束之前,曾为前核心堆栈维护供应商工作。ICL 在一份声明中表示,在接管所有核心堆栈开发后,团队实施了新的安全和招聘协议,从而发现了这个问题,并阻止其进一步的贡献。同一人后来再次申请职位,但被标记并被拒绝。 ICL 表示,自 2 月份以来,它已对所有核心 Cosmos 存储库实施了全面的安全升级,包括撤销旧访问权限、重新许可所有贡献者、轮换凭证以及加强审计控制。 消息来源:The Block

Hot Posts su ICL Group Ltd (ADRs) (ICL)

MrRightClick

MrRightClick

05-08 13:12
Just caught some interesting movement in the medical device space. STAAR Surgical got FDA approval to expand its EVO lens (technically called an Implantable Collamer Lens or ICL) to patients up to 60 years old, up from the previous 45-year limit. Stock popped 8.4% on the news, which makes sense when you dig into what this actually means. The approval is backed by solid clinical data from 629 eyes tracked over three years. Safety profile looks really strong - 1.25 safety index with basically no pupillary block or pigment dispersion issues. Anterior subcapsular cataracts showed up in just 0.16% of cases, which is negligible. Surgeons are clearly buying into this tech too. Data from 19 US refractive practices showed EVO ICL being used in over 70% of high myopia cases (minus 8.0 diopters and above). What's driving this? The refractive correction market is shifting hard. LASIK demand has tanked nearly 40% over the past three years, and patient surveys show 53% of vision correction seekers are now looking at alternatives. That's a massive preference shift. Management estimates there are 24 million myopic adults in the US who could benefit from this ICL approach, with 8 million in that newly approved 46-60 age bracket. The procedure itself is pretty elegant - minimally invasive, preserves your cornea and natural lens, and it's actually reversible. You get immediate vision improvement while keeping options open for future adjustments as your vision changes. That flexibility matters to a lot of patients. Stocks down 37.2% over the past six months, so this approval could be a meaningful catalyst. The broader intraocular lens market is growing too - valued around $5.34 billion in 2026 with a projected 4.72% annual growth rate through 2035. Aging population, rising eye disorder prevalence, and better patient awareness of these options are all tailwinds. One thing to note: the company just appointed interim co-CEOs effective February, so there's some leadership transition happening in the background. But operationally, this age expansion for their flagship ICL product looks like a solid growth driver for the refractive market share going forward.
0
0
0
0
MEV_Whisperer

MEV_Whisperer

04-30 15:13
Just caught wind of some interesting news coming out of the vision correction space. STAAR Surgical got FDA clearance to expand the age range for its EVO Visian ICL procedure - that's the Implantable Collamer Lens for those wondering what icl meaning refers to in medical device circles. They're now approved to treat patients up to age 60 instead of just 45. Pretty significant move. What caught my attention is the underlying data. The approval is backed by three years of FDA clinical trial results from 629 eyes, showing a solid safety profile. We're talking 1.25 safety index at year three, zero cases of pupillary block or pigment dispersion, and only a 0.16% rate of anterior subcapsular cataracts. Those are the kinds of numbers that get surgeons comfortable recommending a procedure. Here's where it gets interesting from a market perspective. Real-world adoption data from 19 US refractive practices shows EVO ICL being used in over 70% of procedures for high myopia cases (patients with -8.0 diopters and above). Meanwhile, laser-based LASIK procedures have tanked - down nearly 40% over the past three years. Patient surveys show 53% of US vision correction consumers are now looking at alternatives to LASIK. The numbers suggest there's a real shift happening. Management estimates 24 million myopic adults in the US could be candidates, including 8 million in that newly approved 46-60 age bracket. In international markets where the 46-60 segment has been available longer, it represents about 6% of their total EVO ICL patient base. Stock-wise, STAA popped 8.4% on the announcement. Over six months though, it's down 37.2%, which puts it underwater against both the broader medical industry and the S&P 500. Current market cap is sitting around $805.82 million. The long-term case seems solid though - as LASIK demand continues declining and more patients opt for lens-based alternatives like ICL procedures, volumes should keep climbing. One other note: the company recently appointed Warren Foust and Deborah Andrews as interim co-CEOs effective February 1st while the board searches for a permanent CEO. That's worth keeping an eye on as leadership transitions tend to create some uncertainty. The broader intraocular lens market is valued around $5.34 billion as of 2026 with expected 4.72% annual growth through 2035, so there's real market expansion happening here. Worth monitoring if you follow the medical device space.
0
0
0
0
BearMarketBard

BearMarketBard

04-30 14:37
Just caught something interesting about the vision correction market that's worth paying attention to. STAAR Surgical got FDA approval to expand the age indication for their EVO implantable collamer lenses—basically, ICL meaning these are permanent lens implants that sit inside your eye to correct myopia. The approval extends eligibility from the previous 21-45 age range all the way to 60 years old, which is a pretty significant move. What caught my eye is the data backing this. Three-year FDA trial results covering 629 eyes showed a solid safety profile—1.25 safety index with virtually zero cases of pupillary block or pigment dispersion. The cataract incidence was minimal at 0.16%. Real-world adoption data is even more telling: surgeons are using EVO ICL in over 70% of procedures for patients with high myopia (-8.0 diopters and above), which suggests a major shift away from laser-based LASIK procedures. The market context makes this even more interesting. LASIK volumes have cratered nearly 40% over three years, hitting multi-decade lows. Meanwhile, 53% of U.S. vision correction consumers are now actively considering alternatives to LASIK. Management estimates there are 24 million myopic adults in the U.S. who could be candidates, with 8 million specifically in that newly approved 46-60 age segment. That's a massive addressable market that was previously locked out. From an investment angle, this positions STAA well in a growing sector. The broader intraocular lens market is valued at $5.34 billion in 2026 and expected to grow at 4.72% CAGR through 2035. With declining LASIK demand and strong surgeon preference for lens-based solutions, the expanded age indication should drive meaningful volume growth. The stock already popped 8.4% since the announcement, though it's still down 37.2% over six months while the S&P 500 gained 8.8%. One thing to note: the company recently appointed Warren Foust and Deborah Andrews as interim co-CEOs effective February 2026, so there's some leadership transition happening in the background while they search for a permanent CEO. Current market cap is around $805.82 million. The reversible nature of ICL procedures—preserving natural corneal tissue and the crystalline lens—appeals to a lot of patients looking for flexible long-term vision strategies. Combined with the safety data and the expanding addressable market, this approval could be a meaningful catalyst for the refractive surgery space. Worth monitoring if you're tracking the medical device sector.
0
0
0
0